<DOC>
	<DOCNO>NCT00630253</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , cyclophosphamide fludarabine , donor stem cell transplant help remove patient 's cell allow transplant cell take grow . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell make immune response body 's normal cell . Giving antithymocyte globulin remove T cell donor cell transplant give cyclosporine transplant may stop happen . PURPOSE : This phase I/II trial study side effect cyclophosphamide , fludarabine , antithymocyte globulin follow donor stem cell transplant see well work treat patient Fanconi anemia .</brief_summary>
	<brief_title>Cytoxan , Fludara , Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant Treating Fanconi Anemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine probability engraftment patient Fanconi anemia treat cyclophosphamide , fludarabine phosphate , antithymocyte globulin follow HLA-genotypically identical sibling donor hematopoietic stem cell transplantation T-cell deplete . Secondary - To evaluate incidence acute graft-versus-host disease ( GVHD ) chronic GVHD patient treat regimen . - To evaluate incidence regimen-related toxicity patient . - To evaluate 1-year survival patient treat regimen . - To evaluate incidence late secondary malignancy ( e.g. , squamous cell carcinoma head neck cervix ) patient treat regimen . OUTLINE : - Preparative cytoreductive therapy : Patients receive cyclophosphamide IV 2 hour day -6 -3 fludarabine phosphate IV 30 minute anti-thymocyte globulin IV 4-6 hour day -6 -2 . - T-cell deplete donor hematopoietic stem cell transplantation : Patients undergo T-cell deplete donor bone marrow umbilical cord blood stem cell transplantation day 0 . Patients also receive filgrastim ( G-CSF ) IV begin day 1 continue blood count recover . - Graft-versus-host disease prophylaxis : Patients receive cyclosporine IV 2 hour orally every 8-12 hour begin day -3 continue day 100 , follow taper . Patients receive Mycophenolate Mofetil ( MMF ) therapy begin day -3 day +30 7 day engraftment , whichever day later , acute GVHD . Engraftment define 1st day 3 consecutive day absolute neutrophil count [ ANC ] &gt; 0.5 x 10^9/L . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients must &lt; 60 year age diagnosis Fanconi Anemia ( FA ) . Patients must HLAA , B , DRB1 identical sibling donor . Patients donor type HLAA B use serological molecular technique DRB1 use high resolution molecular typing . Patients FA must moderately severe aplastic anemia ( AA ) , early myelodysplastic syndrome ( MDS ) excess blast without chromosomal abnormality . In patient &lt; 18 year age , moderately severe aplastic anemia define least one following : platelet count &lt; 40 x 10^9/L absolute neutrophil count ( ANC ) &lt; 10 x 10^8/L Hgb &lt; 9 g/dL In patient 1860 year age , moderately severe aplastic anemia define least one following : platelet count &lt; 20 x 10^9/L absolute neutrophil count ANC &lt; 5 x 10^8/L Hgb &lt; 8 g/dL Early myelodysplastic syndrome , multilineage dysplasia &lt; 5 % blast , without chromosomal anomaly . Adequate major organ function include : Cardiac : ejection fraction &gt; 45 % Hepatic : clinical evidence hepatic failure ( e.g . coagulopathy , ascites ) Karnofsky performance status &gt; 70 % Lansky &gt; 50 % Women child bear age must use adequate birth control negative pregnancy test . Active bacterial infection within one week hematopoietic cell transplant ( HCT ) Active fungal infection time HCT . Late MDS great 5 % blast bone marrow . Acute myelogenous leukemia ( AML ) history AML Malignant solid tumor ( e.g . squamous cell carcinoma head/neck/cervix ) within 2 year HCT . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Fanconi anemia</keyword>
</DOC>